Novotech has opened a Tokyo office to strengthen its clinical development support capabilities in the Japanese market. The Tokyo office is intended to serve as a global development hub connecting the Asia-Pacific region with the US and Europe, accelerating the advancement of development programs in Japan and overseas.
Novotech announced the opening of a new Tokyo office to strengthen its business operations in Japan. The office builds on the company’s track record of supporting clinical trials in Japan and is intended to further strengthen the capabilities available to Japanese companies advancing development programs in Japan and overseas.
The Tokyo office is expected to serve as a hub for deepening expertise rooted in the Japanese market and strengthening collaboration with client companies, partners, research institutions, and the drug discovery and R&D community. It is currently supporting multiple clinical trials in Japan.
Novotech provides comprehensive development support services, including early clinical development support in Australia, assistance with developing protocols that take FDA requirements into account, access to insights from US experts, and access to global business partnership opportunities.
Mori Takeshi (森毅), Novotech’s representative director in Japan, described the opening of the Tokyo office as an important milestone and expressed the company’s commitment to supporting the expansion of international clinical development in Japan. The Tokyo office is located at 27th floor, Shinjuku Island Tower, 6-5-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1327.